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Abstract 
 
Due to the low density of envelope (Env) spikes on the surface of HIV-1, neutralizing IgG 
antibodies rarely bind bivalently using both antigen-binding arms (Fabs) to crosslink between 
spikes (inter-spike crosslinking), instead resorting to weaker monovalent binding that is more 
sensitive to Env mutations. Antibodies capable of bivalently binding within single Env trimers 
(intra-spike crosslinking) should exhibit increased neutralization potencies. Here we consider 
synthetic diFabs joined by varying lengths of rigid double-stranded DNA (dsDNA). We asked 
whether linkers with different rigidities could enhance diFab potency by modeling DNA-Fabs 
containing different combinations of rigid dsDNA and flexible single-stranded DNA (ssDNA) and 
created a model that predicts their neutralization potencies. Model predictions showed that 
although a long flexible polymer may be capable of bivalent binding, it exhibits weak 
neutralization due to the large loss in entropic degrees of freedom during bivalent binding. In 
contrast, the strongest neutralization potencies were predicted to require a rigid linker that 
optimally spanned the distance between two Fab binding sites on an Env trimer. These results 
inform the design of bivalent anti-HIV-1 therapeutics that utilize avidity effects to remain potent 
against HIV-1 in the face of the rapid mutation of Env spikes. 
 
Significance 
 
Effective antibody-mediated immune responses against pathogens involve tight binding to 
invading particles. IgG antibodies usually accomplish this by simultaneously binding two 
antigen-binding arms (Fabs) to a dense array of antigens on the pathogen – if one Fab 
dissociates, IgGs can remain attached through the second arm, enhancing the likelihood that 
the first Fab will reassociate. This avidity effect enables bivalent IgGs to achieve a higher 
apparent affinity for the pathogen than a monovalent Fab. HIV-1 foils this strategy by having few, 
highly-separated, Envelope spikes (Envs) on its surface for IgGs to bind. This forces most anti-
HIV-1 antibodies to bind monovalently, causing IgGs to rapidly dissociate from mutated strains 
of HIV-1 that arise during infection. In this work, we explore the predicted efficacies of an array 
of synthetic antibodies that achieve avidity through bivalent binding to single trimeric Envs. We 
develop a model that uses the geometry of each synthetic antibody to predict its neutralization 
potency, quantifying how entropic effects determine neutralization potencies and presenting a 
way to theoretically design an optimal antibody-based reagent that can bind bivalently to HIV-1 
Env in order to target the virus in the face of its rapid mutation. 
  
.CC-BY 4.0 International licenseIt is made available under a 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/406454doi: bioRxiv preprint first posted online Sep. 3, 2018; 
3 
 
Introduction 
 
Despite decades of research since its discovery, Human Immunodeficiency Virus-1 (HIV-1) 
continues to threaten global public health (1). While there have been advances in our 
understanding of the mechanisms of infection and the development of preventative and 
therapeutic strategies, there remains no cure for HIV-1 infection. Antiretroviral therapy with 
small molecule drugs can control the progression of the virus, allowing those infected with HIV-1 
to live longer and healthier lives, but the treatment includes detrimental side effects, and when 
discontinued or not taken as prescribed, leads to viral rebound to pre-treatment levels (2). A 
major factor confounding the development of a prophylactic vaccine is the rapid mutation of 
HIV-1, leading to the emergence of many new strains, even within a single individual (3). Thus 
most antibodies raised by the host immune system are strain-specific or neutralize only a subset 
of strains, leading to viral escape from host antibodies.  
 
Recent interest has focused upon the isolation of broadly neutralizing IgG antibodies (bNAbs) 
from a subset of HIV-1–infected individuals (4). These antibodies bind to and block the functions 
of the HIV-1 envelope (Env) spike, the viral protein responsible for fusion of the HIV-1 and target 
cell membranes that leads to entry of the virion’s genetic material into the host cell (5). The 
discovery and characterization of HIV-1 bNAbs has brought new impetus to the idea of 
passively delivering antibodies to protect against or treat HIV-1 infection. bNAbs can prevent 
and treat infection in animal models (6-12) and exhibited efficacy against HIV-1 in human trials 
(13-16). However, HIV-1 Env mutates to become resistant to any single bNAb, as evidenced by 
the fact that NAbs developed in an infected individual, even NAbs that can neutralize large 
numbers of viral variants in laboratory assays, normally fail to neutralize autologous circulating 
viral strains (17-20). As a result, antibodies that develop during HIV-1 infection appear to be 
unable to control the virus in an infected individual. 
 
We previously proposed that one mechanism by which HIV-1 evades antibodies more 
successfully than other viruses arises from the low surface density of Env spikes that can be 
targeted by neutralizing antibodies (21). Compared to viruses such as influenza A, dengue, and 
hepatitis B, the density of Env spikes on the surface of HIV-1 is about two orders of magnitude 
smaller (21). For example, influenza A has ≈450 spikes per virion, whereas each HIV-1 virion 
incorporates only 7-30 Env spikes (average of 14) (21-25), even though both are enveloped 
viruses with ≈120 nm diameters (Fig. 1A). The HIV-1 spikes are the machinery by which the 
virus binds its host receptor CD4 and coreceptor CCR5/CXCR4 to mediate the fusion of the 
host and viral membranes that allows its genome to enter target cells (5). As a consequence of 
its small number of spikes, HIV-1 infection of target cells is inefficient; the transmission 
probabilities for sexually-acquired HIV-1 infection range from 0.4 to 1.4% (26). However, the 
reduced infectivity of HIV-1 comes with a concomitant reduction in the ability of antibodies to 
control the virus, as the surface spikes serve as the only targets for neutralizing antibodies that 
can block infection of target cells (4).  
 
The close spacing of spikes on typical viruses allows IgG antibodies to bind bivalently to 
neighboring spikes (inter-spike crosslinking) using both of their antigen-binding arms (Fabs). 
However, most spikes on HIV-1 virions are too far apart to permit inter-spike crosslinking by 
IgGs, whose antigen-binding sites are separated by ≤15 nm (27). While each homotrimeric HIV-
1 spike includes three binding sites (epitopes) for an antibody, the architecture of HIV-1 Envs 
and distribution of epitopes on the HIV-1 Env trimer prohibits simultaneous binding of two Fabs 
within a single IgG (intra-spike crosslinking) to the same Env (28, 29). We suggested that 
predominantly monovalent binding by anti-HIV-1 antibodies expands the range of Env mutations 
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permitting antibody evasion, whereas reagents capable of bivalent binding through inter- or 
intra-spike crosslinking would be more resistant to Env mutations and thus more potent across 
multiple strains of HIV-1 (21). The hypothesis that HIV’s low spike numbers and low densities 
contributes to the vulnerability of HIV-1 bNAbs to spike mutations is supported by independent 
biochemical and EM studies demonstrating that HIV-1 has an unusually low number of spikes 
that are not clustered (22-25, 30), and that bivalent IgG forms of anti-HIV-1 NAbs are only 
modestly more effective than monovalent Fabs, by contrast to bivalent IgGs against other 
viruses, which can be 100s- to 1000s-fold more potent than counterpart monovalent Fabs (21, 
28, 29). 
 
An antibody’s neutralization potency against a virus is related to its antigen-binding affinity, 
which is defined as the binding strength between a Fab and its antigen (31) described by the 
equilibrium dissociation constant KD = [Fab][Ag]/[Fab–Ag], where [Fab], [Ag] and [Fab–Ag] are 
the concentrations of the antibody Fab, antigen, and the complex, respectively (32). In bivalent 
molecules interacting with binding partners that are tethered to a surface, the apparent affinity, 
or avidity, can be enhanced by multivalent binding. Such multivalent interactions are seen in 
many biological contexts including cell-cell communication, virus-host cell interactions, antibody-
antigen interactions, and Fc receptor interactions with antigen-antibody complexes (33). Avidity 
effects benefit these interactions from both kinetic and thermodynamic standpoints: binding 
bivalently to tethered binding partners is advantageous kinetically because if one arm 
dissociates, the likelihood of it finding its binding partner is greater due to the constraint of being 
tethered (34). Avidity effects are also advantageous thermodynamically; whereas binding the 
first arm results in losses of translational and rotational degrees of freedom, the subsequent 
binding of the second arm incurs a smaller entropic cost, thereby increasing the likelihood of the 
bivalent state (34).  
 
In the context of an IgG with two antigen-binding Fabs, the ability to bind bivalently is dependent 
on geometric factors such as the separation distances and orientations of tethered epitopes (35). 
In the case of IgG-virus interactions, the tethered epitopes would be on adjacent spikes during 
inter-spike crosslinking or on individual spikes if intra-spike crosslinking can occur. Although the 
architecture of the HIV-1 spike prevents intra-spike crosslinking (28, 29), it is possible to 
engineer reagents (homo- and hetero-diFabs) that can simultaneously bind to a single spike 
trimer. Our intra-spike crosslinking reagents were IgG Fabs joined by different lengths of 
double-stranded DNA (dsDNA), which served as both a rigid linker and a molecular ruler to 
probe the conformations of HIV-1 Env on virions (36) (Fig. 1B). Optimal diFabs should inhibit 
HIV-1 infection of reporter target cells more efficiently than the parental IgG or Fab. Since 
dsDNA behaves as a rigid rod for lengths up to 150 bps (37), the length of the dsDNA linker 
between the two Fabs could be used as a ruler to measure the approximate distance between 
epitope binding sites on virion Envs and to design reagents capable of strong intra-spike 
crosslinking between such sites.  
 
While a rigid, optimal-length linker joining two HIV-1 bNAb Fabs should result in synergistic 
binding and neutralization of HIV-1 through avidity effects, we cannot rule out the possibility that 
a flexible linker joining two Fabs could also enhance potency. For example, if maximal potency 
in an intra-spike crosslinking diFab does not require a rigid linker spanning the precise distance 
between epitopes on trimeric HIV-1 Env, it should be possible to create IgGs that bind with 
avidity to any Env epitope using a protein-based flexible linker. A more flexible linker could 
potentially improve the antigen-binding orientation and hence affinity of the Fab, but it would 
also increase the entropic penalty associated with bivalent binding (34). To investigate which 
effect was dominant, flexible Gly4Ser repeats were introduced into the hinge regions of IgGs to 
extend their reach, but the resulting constructs did not show increased potencies (38).  
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In this work, we modeled the predicted effects of 11 diFabs with DNA linkers to model the 
effects of linker rigidity on synergistic neutralization by a diFab constructed from the CD4-
binding site bNAb 3BNC60. Starting with (d=62, s=12) (two 3BNC60 Fabs joined by a 62 bp 
(base pair) dsDNA linker flanked by 12 bases of ssDNA on both ends (36)), we considered new 
linker designs in order to predict the roles of rigidity and flexibility versus overall length of DNA 
linker within a series of 3BNC60 diFabs. We created a statistical mechanics-based 
mathematical model that characterized the various synthetic antibodies we created, which 
suggested that the efficacy of intra-spike crosslinking/increased neutralization potency could be 
explained solely by entropic effects. Using this model, we can predict the neutralization potential 
of other synthetic bivalent antibodies and of more complicated geometries involving additional 
Fabs. Insights from our synthetic constructs can be adapted to antibody design in other systems 
in which length and rigidity of linkers in multivalent reagents must be balanced to elicit the most 
effective response. 
 
Results 
 
Parameters for modeling 
To evaluate our hypothesis that anti-HIV-1 reagents that bind bivalently would be more potent 
across multiple strains of HIV-1 (21), we previously engineered antibody-based molecules to 
bind bivalently through intra-spike crosslinking (36). This was accomplished by making a library 
of bNAb Fabs, covalently attached them to ssDNA, and then hybridizing the ssDNA to different 
lengths of dsDNA to make diFabs connected by different lengths of dsDNA (Fig. 1B). We 
hypothesized that the dsDNA in the bridging linker served as a molecular ruler by virtue of its 
long persistence length (dsDNA is essentially rigid up to ≈150 bp) and its 0.34 nm/bp increment 
(37). Optimal dsDNA linker length for the 3BNC60 diFab can be determined by evaluating 
dsDNA linkers using in vitro neutralization assays in which different concentrations of a 
synthetic antibody were evaluated for their ability to prevent HIV-1 infection of target cells (39). 
We previously found that the 50% inhibitory concentrations (IC50 values) of 3BNC60 diFabs 
were low (i.e., indicating potency) when the diFabs contained 62 bp of dsDNA with 12 bases of 
flanking ssDNA on both sides of the linker (36). We hypothesized that this diFab, here called 
(d=62, s=12), exhibited synergistic neutralization resulting from avidity effects due to intra-spike 
crosslinking in which the diFab bound to two of its three adjacent epitopes on a single HIV-1 
Env trimer. The length of the double-stranded region of this linker (21 nm) was close to the 
predicted distance (≈20 nm) between the C-termini of adjacent 3BNC60 Fabs (where the DNA 
was covalently attached) bound to a low-resolution open structure of an HIV-1 trimer (40).  
 
To model the linkers connecting the two Fabs in our synthetic antibodies, we treated the dsDNA 
as a 1D rigid rod and the ssDNA as a random walk. The former assumption is valid when the 
linkers in constructs include ≤100 bp of dsDNA, less than its 150 bp persistence length (41). 
Free ssDNA is flexible with a persistence length between 2-6 bases (42, 43), and because each 
of our the constructs we considered consisted of ssDNA segments with at least 12 bases, we 
analyzed the ssDNA as a floppy chain using polymer physics models (e.g., the ideal chain 
model, the worm-like chain model) (44).  
 
The contribution of the ssDNA was modeled in two ways: (1) a model in which the ssDNA in the 
diFab linker was ignored by assuming it has zero length (Fig. 2A) and (2) a model in which the 
ssDNA contributed to the linker but with a smaller persistence length than when free in solution 
(Fig. 2B).  
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Another model parameter,  
 
, was included to account for variations in the distance between 
the C-termini of the two 3BNC60 CH1 domains to which the DNA was attached due to the 
following factors: (i) The Fab CH1-CL domains can adopt different conformations with respect to 
VH-VL (45) such that the locations of the CH1 C-terminus could shift by up to ≈1 nm, (ii) Residues 
C-terminal to CH1 residue 217 are disordered in the 3BNC60 Fab structure (46), thus the 
position of the CH1 residue to which the DNA was attached (Cys233) is uncertain within ≈1 nm, 
(iii) The ssDNA is covalently linked to the CH1 residue Cys233 using an amine-to-sulfhydryl 
crosslinker (Sulfo-SMCC) (36), which would exert unknown effects on the length and the degree 
of flexibility between the ssDNA and Fab.  
 
Relating Antibody Neutralization to the Probability that an HIV-1 Spike is Bound 
We next created a mathematical model of diFab efficacy based on the properties of the linker. 
To lay the groundwork for this model, we first related the ability of a diFab to neutralize an HIV-1 
virion to the probability that an Env spike on the surface of HIV-1 will be bound. Each Env spike 
is a homotrimer with three identical binding sites for a 3BNC60 Fab (47). The spikes are 
assumed to be sufficiently far apart that a diFab cannot crosslink between neighboring spikes. A 
diFab with the right geometry can bind to two binding sites on the same spike, whereas a diFab 
whose linker is either too short or too long can bind to only a single Env epitope. 
 
Previous experiments suggested that only one of the three CD4 binding sites on an Env spike 
need to be bound to prevent the Env from functioning in membrane fusion (48). We imposed a 
soft threshold for virus entry where the ability of an HIV-1 virion to infect increases linearly from 
zero (when all spikes are bound by diFabs) to some maximum value (when all spikes are 
unbound) that is constant across all HIV-1 molecules (Appendix A). While some studies 
suggested that two or three Env trimers are required for HIV-1 to infect (49, 50), other studies 
found that only one functional Env trimer was required for target cell fusion (51); thus our model 
allowed a virion with a single unbound Env trimer to infect, albeit 1/ as effectively as a virion 
with  unbound trimers.  
 
Given these assumptions, the ability of a diFab to neutralize HIV-1 is proportional to the 
probability that at least one of the CD4 binding sites of an HIV-1 spike will be bound by a 
3BNC60 Fab (Appendix A). For example, if each Env protein has a 75% chance to be bound by 
a diFab, an average of 75% of the spikes on each virion will be bound, and by the linearity 
assumption, the HIV virions will be 75% neutralized. This enables us to relate the % 
neutralization for diFabs to the theoretically-tractable probability that a single Env spike will be 
bound either monovalently or divalently by a diFab. Avidity effects will allow an optimal diFab to 
bind more tightly (with a lower apparent KD) to a spike, increasing the binding probability and the 
neutralization potency. 
 
Modeling the Avidity of a diFab if it is Constrained by the Length of Rigid dsDNA and 
Essentially Independent of Flanking Flexible ssDNA 
To calculate the probability that any of the 3BNC60 binding sites on an HIV-1 spike are 
occupied, we enumerated three potential states of the spike, which represent a single diFab 
bound to zero, one, or two adjacent binding sites. We first modeled the system as a pair of Fabs 
joined together with dsDNA and ignored the contributions of the ssDNA (Fig. 2A). 
 
When a diFab transitions from the unbound state (with probability 

) to a monovalently-bound 
state (with probability 

), it loses translational and rotational entropy but gains favorable binding 
energy (52) leading to the relative probability 
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where 

	
 is the equilibrium dissociation constant of the first diFab arm binding to Env. Note 
that 

	
 incorporates the geometry of the Env trimer, namely, that there are three 3BNC60 
binding sites on a trimeric HIV-1 spike and that the diFab can bind monovalently with either arm. 
Importantly, the transition from an unbound to a monovalently-bound diFab is independent of 
the composition of the diFab’s linker, since the loss in translational and rotational entropy 
increases slowly with the size of a particle and hence can be assumed to be the same for all 
constructs. This implies that the constant 

	
 will be the same for all diFabs and that it also 
characterizes the 3BNC60 Fab’s binding to the Env trimer. By assuming that the neutralization 
potency of the Fab is proportional to how well it binds to the HIV-1 spike, the value of 

	
 is 
given by an experimentally-determined Fab IC50 value for the 3BNC60 Fab against the 6535.3 
strain of HIV-1 74 ! 31 nM) (Fig. 3B), a value consistent with experimental KD values reported 
for binding of a Fab from a CD4-binding site bNAb to a soluble, trimeric form of HIV-1 Env 
derived from a different HIV-1 strain (53). In viral contexts in which the relationship between the 
apparent KD of an antibody and its IC50 is more complex, the dissociation constant could instead 
be inferred by nonlinear fitting.  
 
We now turn to the transition from a monovalently-bound diFab to a bivalently-bound diFab. The 
ability to bivalently bind strongly depends on the size of the diFab’s linker, since having too large 
or too small a linker will preclude bivalent binding through intra-spike crosslinking. The relative 
probability of each energy state is proportional to its Boltzmann weight, #

	  Ω #
, 
where %  

 

, & is the energy, ' is the temperature (37˚C), (

 represents Boltzmann’s 
constant, )  (

log Ω is the entropy, and Ω is the number of microstates with a given energy. 
Thus, the relative probabilities of the bivalent and monovalent states satisfy  
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where 

, &

, and Ω

 represent the probability, energy, number of microstates when , Fabs are 
bound to an Env. 
 
The number of configurations Ω

 for a monovalently-bound diFab is proportional to the degrees 
of freedom available when one Fab is bound to its epitope and the second Fab is unbound and 
tethered to the first by DNA. Since the associated entropy of this motion increases slowly with 
size, we assume that Ω

 is constant across all diFabs. Similarly, the binding energy &

- &

 
gained when the second Fab in a diFab binds to the HIV-1 spike is the same for all diFabs we 
consider. 
 
The number of configurations Ω

 of the bivalent state depend upon the entropy of the dsDNA 
linker joining the C-termini of the two bound Fabs separated by a width  

 (Fig. 2A). In 
addition, each Fab is inherently flexible at the join between the CH1-CL domains and the VH-VL 
domains, as denoted by  
 
. If we approximate  

 and  
 
 as colinear so that the problem 
becomes one dimensional (see Appendix B), the number of microstates corresponding to the 
bivalently-bound state satisfies 
Ω

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where  

1
 equals the length between the outer-most dsDNA orientations capable of 
bivalent binding (Appendix B Fig. S2), and Δ  is a constant representing the discretization of this 
length so that Ω

 is unitless. In short,  

1
 quantifies how the geometry of the diFab affects 
its ability to bivalently bind to a spike. 
Using Eqs. Error!  Bookmark not deined.-Error!  Bookmark not deined. and the normalization 
condition, 

4 

4 

 1, the probability that at least one of the three Fab epitopes on an HIV-
1 spike will be bound can be written as 
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where we have separated the constant 5  
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, which does not depend on the diFab 
geometry, from  

1, which does. Because 

4 

 is proportional to the % neutralization of 
the HIV virion, the IC

 of each diFab with the contribution of the ssDNA excluded is given by  
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We proceed by assuming that the dissociation constant takes the value 
!
	
 74 nM, which 
characterizes the first diFab arm binding to Env. We further assume an optimal linker length 
 

 21 nm between bound Fabs, the flexibility  
 
 1.8 nm between the Fab CH1-CL and 
VH-VL domains, and the avidity constant 5  70. Fig. 2D (gray line) shows the model predictions, 
which roughly approximate the shape of the IC50 values. diFabs that are too long or too short 
cannot bivalently bind, leading to a sharp transition in the IC50 for dsDNA shorter than  

-
 
 
 19.2 nm (57 bp) or longer than  

4  
 
 22.8 nm (69 bp). We hypothesized that 
including the ssDNA in the model would smooth the transition from the bivalent to purely 
monovalent binding, and next explored how the effects of the ssDNA in the linker could be 
modeled. 
With contributions of ssDNA included, the distance  

 between the C-termini of bivalently 
bound Fabs must be spanned by the rigid dsDNA segments as well as the two flanking ssDNA 
strands (Fig. 2B). We modeled each ssDNA segment as a random walk using an ideal chain 
model with a persistence length of ;

 0.1 nm.  
 
Of the multiple configurations that two ssDNA random walks can take on, only a small fraction 
will end at the proper distance  

 to allow a diFab to bivalently bind. The probability density 
that the linker will obtain one of these limited configurations can be computed analytically 
(Appendix C) as  
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Error!  B
where  

 B C0.34
(
)*
D and  

 E C0.64
(
)+
D represent the length of dsDNA and ssDNA 
segments in the linker, respectively. Analogously to Eq. 3, the flexibility of the Fab implies that 
the dsDNA and ssDNA can span any length from  

-  
 
 to  

4  
 
 (see Appendix C). 
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In the limit where 1 nm G  
 
H  

G 20 nm, the number of bivalent configurations is 
proportional to the simple form 
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As in the model neglecting ssDNA described in the previous section, all other constants that are 
independent of the diFab geometry can be absorbed into a prefactor 5I in the bivalent state (Fig. 
2B). Thus, the occupancy probability for an HIV-1 spike is given by the same functional form as 
Eq. Error!  Bookmark not deined., namely, 
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with an analogous IC50 given by 
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We proceed with the physiologically reasonable parameter values 
!
	
 74 nM,  

 21 nm, 
 
 
 1.8 nm, 5I  5.2 K 10

, and the ssDNA persistence length ;

 0.1. The avidity 
parameter 5I is orders of magnitude larger than the corresponding parameter (5  70) in the 
model neglecting ssDNA because the probability that the 3D random walk encompassed within 
I

 

,  

1
 will end at the particular distance to enable bivalent binding is small, thereby 
requiring a correspondingly larger avidity parameter. 
 
Fig. 2C plots the probability that a diFab will be bivalently bound (

) relative to the 
monovalently bound probability (

) as the amount of dsDNA (d) and ssDNA (s) in the linker 
varies. The model captures the trend that bivalent binding is most likely when  

G  

 
around d=62 bp dsDNA, with the peak shifting very slightly leftwards as the amount of ssDNA 
increases, demonstrating how the root-mean-squared length of the ssDNA slowly increases. 
The black curve in Fig. 2D shows how the model incorporating ssDNA (Eq. 9) provides a 
broader transition of the bivalent to monovalent binding. For the remainder of the paper, we 
restrict our analysis to this latter model that includes the contributions from both ssDNA and 
dsDNA within the linker. 
 
The diFab Model Allows Bivalent Binding Only when the dsDNA Length is Approximately 
Equal to the Length of the Linker it Spans 
To gain a qualitative understanding of the model including ssDNA (Eq. 9), we examined it in two 
limits: near an optimal geometry  

G  

 where the ability to bind bivalently is maximum, 
and far from the optimal limit when the diFab is too short or too long to permit bivalent binding 
through intra-spike crosslinking. Note that all these statements also hold for the model excluding 
ssDNA (Eq. 5) provided 5I L 5 and I L . 
 
Near the optimal limit, corresponding to  
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 or B G 62 bp, HIV-1 neutralization will 
occur predominantly from the bivalently-bound configuration rather than the monovalent state, 
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N 1. Hence, the system is well approximated with each spike either 
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corresponding to the trough in the black curve in Fig. 2D. If the potency of diFab 1 is IC
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the potency of diFab 2 with a different linker is IC
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In other words, the relative potency of both diFabs is determined solely by the separation 
distances between the two Fabs in the diFabs, so that the entropy, rather than the energy, 
determines which diFab will be more effective.  
 
When the linker in a diFab becomes too small ( 
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shown as a pink dashed line in Fig. 2D.  
 
Altering the Fraction of ssDNA and dsDNA in the Linker 
We next modeled how well the probability of diFab binding (Eq. 9) quantitatively characterized 
the neutralization of new diFab constructs. We first tuned the rigidity of the linker while keeping 
the length of the DNA segment fixed. Starting with the optimal construct (d=62, s=12), five new 
diFabs were considered with different amounts of dsDNA d flanked by two ssDNA segments s 
maintaining d+2s=86 bases (Fig. 3A). Fig. 3B shows how the predicted behavior of these 
constructs using our model. 
  
Extra Long ssDNA Segments are Characterized by a Short Persistence Length 
We next modeled diFabs with extra long ssDNA regions to investigate whether the ssDNA in 
this limit has an appreciable effect (Fig. 4A). If the size of the ssDNA grows slowly with its length, 
we would expect that constructs with increased ssDNA, such as (d=62, s=17) and (d=62, s=42), 
would neutralize less potently than their counterpart (d=62, s=12) with the same length of 
dsDNA.  
 
Adding ssDNA Gaps makes dsDNA Flexible and Decreases diFab Efficacy 
As a final probe of the effects of linker flexibility, we investigated the potency of two diFabs in 
which the dsDNA linker was interspersed with short ssDNA segments (Fig. 5A). These 
constructs, denoted by (5105105105) and (5105225105), contained the same lengths of DNA as 
(d=50, s=12) and (d=62, s=12). However, the dsDNA in (5105105105) and (5105225105) was 
flanked by an extra 5 bases of ssDNA on both sides and interrupted in two places by 5 bases of 
ssDNA.  
 
Our model can be generalized to analyze these constructs by considering the inner ssDNA 
segments as simple hinges with no length so that the dsDNA can now be characterized as a 
random walk composed of three steps (Appendix F). The two outer ssDNA segments can be 
modeled as a random walk with a persistence length of 0.1 nm. For the larger of the two 
constructs, (5105225105), the 42 bp of dsDNA would account for a maximum of only 14 nm when 
arranged linearly, thus the two outer ssDNA segments would have to stretch outwards by at 
least 7 nm (11 bases) to achieve the optimal separation distance of 21 nm in the unlikely event 
that all of the DNA segments were colinear. The shorter construct in Fig. 5A (5105105105) would 
require the ssDNA to stretch even further to achieve maximal potency. Hence, the two gapped 
diFabs should only bind monovalently with an IC50 given by Eq. 12, as confirmed by the model 
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in Fig. 5B. Note that even if the dsDNA region of the linker were made longer, increasing the 
dsDNA flexibility in this manner increases the entropy lost when going from the monovalently- to 
bivalently-bound states and hence decreases the neutralization potency of the diFab. In 
Appendix F, we use the model to quantify the decrease in potency as the dsDNA in the optimal 
(d=62, s=12) construct is broken into multiple segments. 
 
Discussion 
 
The low density of Env spikes on HIV-1 potentially enables the virus to mitigate the host 
antibody response by hindering host IgGs from using both antigen-binding Fabs to bind 
bivalently, thereby expanding the range of HIV-1 mutations permitting antibody evasion (21, 36). 
The observation that a mutant simian immunodeficiency virus (SIV) with a higher number of Env 
spikes reverted to its normal spike number of ≈14 when propagated in non-human primate hosts 
is consistent with selection against those viruses that facilitate the ability of host IgGs to bind 
bivalently through inter-spike crosslinking (54). Although HIV-1 may be more infectious and 
hence spread more rapidly with more Env trimers (55), the immune system apparently applies 
selective pressure that keeps the Env spike count per virion low, presumably to prevent anti-
HIV-1 IgGs from utilizing avidity effects to counter the lower intrinsic Fab-Env affinities that 
result from rapid mutation of Env. Antibody isotypes such as dimeric IgA or pentameric IgM 
have increased valencies (four and ten Fabs, respectively) compared to the two Fabs of an IgG, 
thus allowing for increased avidity effects during antibody binding to a pathogen. However, most 
of the neutralizing activity in the sera of HIV-1–positive individuals is attributed to IgGs (56, 57), 
and converting an anti-HIV-1 IgG broadly neutralizing antibody to an IgA or IgM has minimal 
effects on potency in standard neutralization assays (58, 59). Thus, most antibodies against 
HIV-1 Env must resort to monovalent binding by IgGs in the absence of avidity effects that 
would strengthen their interactions with other pathogens. 
 
Bivalent binding to single Env trimers is another way to utilize avidity effects to counteract the 
low spike density of HIV-1. Although the architecture of HIV-1 Env trimers prohibits 
simultaneous binding of both Fabs of conventional, host-derived IgGs (28, 29), we constructed 
synthetic antibodies (Fig. 1B) (diFabs constructed from Fabs from a neutralizing anti-HIV-1 IgG 
joined by a linker containing rigid dsDNA flanked by flexible ssDNA) designed to achieve intra-
spike crosslinking; i.e., bivalent binding to adjacent Fab binding sites on a single Env trimer. In 
previous work, we measured the neutralization potencies of an array of diFabs with different 
dsDNA lengths and found that the linker in the optimal 3BNC60 diFab had 62 bp (21 nm) 
dsDNA. 
 
The optimal 21 nm length of the dsDNA portion of the linker can be compared to the distance 
between adjacent 3BNC60 Fabs in various conformations of HIV-1 Envs. It has been shown 
that HIV-1 Env trimers adopt multiple conformations on virions (23, 60) and in the soluble 
native-like forms used for structural studies (47). For example, binding of the host CD4 receptor 
induces outward displacements of the three Env gp120 subunits, resulting in an open 
conformation in which the coreceptor binding sites on the trimer apex V3 loops are exposed (61-
64) and which rearranges further upon coreceptor binding and subsequent membrane fusion. 
We measured the distances between adjacent 3BNC60 epitopes on Env trimers in different 
conformations using a new cryo-EM structure of 3BNC117 Fab (a close relative of 3BNC60 
(46)) bound to a closed Env trimer (65). Measurements from this single-particle cryo-EM 
structure allows estimation of the average position of the C-terminal CH1 domain residue to 
which the DNA in our diFabs was covalently attached, since Fabs in cryo-EM structures are not 
influenced by crystal packing forces that can alter the CH1-CL domain position relative to the VH-
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VL domains in X-ray structures (45). We used the 3BNC117 Fab-gp120 portion of the cryo-EM 
structure to measure the distance between adjacent Fab CH1 C-termini in the closed 
conformation of Env and then modeled a 3BNC60-gp120 protomer into three recent cryo-EM 
structures of Env trimers in different conformations: an open Env bound by the b12 bNAb in 
which the coreceptor binding sites on the V3 loops are not exposed (62), an open CD4-bound 
Env structure with exposed V3 loops (62), and a partially-open CD4-bound Env in which the 
gp120 subunits adopted positions mid-way between closed and fully open (63). From these 
structures, we measured distances of 15.8, 20.3, 20.4, and 20.1 nm between C-termini of 
3BNC60 Fab CH1 domains modeled onto the closed, b12-bound open, CD4-bound open, and 
CD4-bound partially-open Env conformations, respectively (see Methods). Although monovalent 
CD4-binding site bNAb Fabs bind the closed Env trimer conformation (47), the 21 nm length of 
the dsDNA in the optimal (d=62, s=12) diFab more closely matched measured distances for the 
open Env trimer structures, perhaps indicating that the diFab captured an open Env 
conformation that could be neutralized potently by a reagent binding through intra-spike 
crosslinking. 
 
In this work, we consider an array of diFabs with variable amounts of rigid dsDNA and flexible 
ssDNA, enabling us to tune both the length and rigidity of the DNA linker. In order to provide a 
conceptual framework to understand how these synthetic antibodies function, we developed a 
statistical mechanics-based model to predict diFab potencies for inhibiting infection of the 
6535.3 strain of HIV-1. By assuming that (i) each homotrimeric spike is unable to help infect a 
host cell when any one of its three epitopes are bound by Fab, and (ii) that the infectivity of a 
virion varies linearly with the number of unbound Env, we showed that the neutralization of a 
virion is proportional to the probability that any single Env protein is bound by a Fab (Appendix 
A). This framework enabled us to translate the linker-dependent entropy and energy of binding 
to an HIV-1 Env trimer into a predicted neutralization potency for each diFab.  
 
The first set of diFabs we created explored the effects of linker rigidity. These constructs had the 
same total length of DNA (86 bases) but differed in their fractions of dsDNA and ssDNA (Fig. 3). 
We found that as the dsDNA decreased from the optimal d=62 to d=58, 50, 40, 30, and 20 bp, 
the potency of the antibodies rapidly decreased so that the four constructs with d≤50 neutralized 
only as effectively as the monovalent Fab. From a modeling perspective, the short ssDNA 
persistence length implies that the ssDNA plays a minor role in determining diFab potency. 
Hence, the constructs composed of d bp dsDNA and s=(86-d)/2 bases ssDNA should behave 
similarly to the constructs with d bp dsDNA and s=12 bases ssDNA. In other words, decreasing 
the dsDNA length shortened the length of the diFabs to the point where only monovalent 
binding was possible when d≤50. A second set of diFabs explored whether extra long ssDNA 
segments can alter diFab potency (Fig. 4). The observed effects were minor, reaffirming that the 
length of dsDNA in the linker has greater impact on diFab potency than the length of ssDNA. 
Finally, we considered two additional diFabs that introduced ssDNA gaps within the dsDNA 
portion of the linker (Fig. 5). As in the above two cases, the model predicts that both constructs 
should exhibit poor neutralization potencies comparable to that of a monovalent Fab (see 
Appendix F). 
 
We point out several factors of the HIV-1 system that the model neglects. First, the model does 
not consider potential diFab binding between adjacent Env trimers, although this binding should 
be minimal given the low density of Env on the virion’s surface. Second, our model assumed 
that the % neutralization of HIV-1 decreases linearly with the number of unbound Env trimers 
(Appendix A); such a linear relationship has been observed when less than half the HIV-1 
spikes are bound (55), although it may not hold when more than half of the spikes are bound 
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(possibly because some minimum number of unbound Env trimers are needed to successfully 
infect a cell). In a similar vein, we neglected the variability in the numbers of spikes per virion 
(22-25), instead assuming that all virions had exactly 14 spikes. However, relaxing these 
assumptions yielded nearly identical results (Appendix A), suggesting that the model is robust to 
these assumptions. 
 
A compelling extension of this work that would deepen our understanding of the antibody 
response against HIV-1 would be to consider reagents with more than two Fabs. As has been 
seen in other biological systems (66-68), synthetic antibodies with greater valency can elicit 
tighter binding. Hence, a triFab that allows three Fabs to simultaneously bind to an HIV-1 Env 
trimer is predicted to have a lower IC50 than an optimal diFab; indeed, our model predicts that 
an optimal triFab would have an IC50 that is 100x more potent than the optimal (d=62, s=12) 
diFab (see Appendix F). Modeling verifies that a rigid linker is required for a bivalent or trivalent 
reagent to achieve avidity effects by intra-spike crosslinking, thus providing guidance for 
constructing optimal anti-HIV-1 therapeutics that remain potent against HIV-1 in the face of the 
Env mutations arising during HIV-1 replication.  
 
Multivalency has been harnessed in an array of fields that extend beyond immunology; e.g., 
novel materials and scaffolds have been designed at the super-cellular scale using multivalency 
(69), and molecular targeting and molecular machines employ multivalency at the molecular 
scale (68, 70, 71). We hope that our work presents a step towards precise, quantitative models 
that encompasses multivalent binding in each of these contexts. 
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Methods 
Measurements of Separation Distances on Env Trimer Structures 
We used a single-particle cryo-EM structure (65) of a closed Env trimer bound to 3BNC117, a 
3BNC60-related bNAb (46) for estimating the position of position of CH1 residue 233 (to which 
the DNA linker in the 3BNC60 diFabs was attached) when a 3BNC60 diFab is bound to an Env 
trimer. The coordinates for the VH-VL domains of the 3BNC60 Fab (46) were superimposed on 
the 3BNC117 VH-VL domains, and the coordinates for the CH1-CL domains from the structure of 
b12 IgG (27) were superimposed on the 3BNC117 CH1-CL domains because CH1 residues 217 
– 233 are disordered in the 3BNC60 Fab structure (46). The model for the 3BNC60 Fab-gp120 
portion of the trimeric cryo-EM complex structure was used to measure the distance between 
adjacent Fab CH1 C-termini in the closed conformation of Env and then modeled into three cryo-
EM structures of Envs in different conformations: an open Env bound by the b12 bNAb in which 
the coreceptor binding sites on the V3 loops are not exposed (62), an open CD4-bound Env 
structure with exposed V3 loops (62), and a partially-open CD4-bound Env in which the gp120 
subunits adopted positions mid-way between closed and fully open (63).  
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Fig. 1. Effects of spike density on IgG binding. (A) Close spacing of hundreds of surface spikes on 
influenza A allows bivalent binding of IgGs to adjacent spikes (red boxes), permitting avidity effects in the 
context of low monovalent (i.e., Fab-antigen) affinities. In contrast, HIV-1 has an average of 14 spikes that 
are spaced far apart, and because the HIV-1 spike architecture prohibits simultaneous binding of two 
Fabs to a single Env trimer, most IgGs bind monvalently to HIV-1 Envs (gold boxes). We investigated a 
synthetic homo-diFab designed to bind bivalently to a single HIV-1 spike trimer (blue boxes). (B) 
Schematics of a Fab, an IgG, and a diFab composed of two Fabs joined by a ssDNA and dsDNA linker of 
length d bp flanked on both sides by s=12 bases of ssDNA. 
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Fig. 2. Modeling the optimal linker length for a diFab. (A) DLS data suggested that the diFab linker 
can be modeled by either (A) ignoring the ssDNA entirely or (B) including the ssDNA with a smaller 
persistence length. In both models, the Boltzmann weight of the monovalent state is dictated by the  
 

 
(the dissociation constant between the Env trimer and the first diFab arm), while the weight of the bivalent 
state is dictated by a geometric or avidity factor (  in Panel A and    in Panel B) shown in a gray box. 
This geometric factor depends upon the length of the dsDNA and ssDNA in each construct as well as on 
the optimal length 
	

 of the linker between two bound Fabs and the flexibility 
	
 between the CH1-CL 
and VH-VL domains of a bound Fab. The ability to neutralize is given by the sum of the probabilities of the 
monovalent and bivalent states. (C) The relative probability that a diFab with d bp dsDNA and s bases 
ssDNA in its linker is bivalently (

) versus monovalently (

) bound. (D) Predicted effects of dsDNA 
bridge lengths on the neutralization potencies of the 3BNC60 diFabs against HIV-1 strain 6535.3. 
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Fig. 3. Effects of linker rigidity on diFab potency. (A) Schematics of 3BNC60 diFabs with different 
proportions of dsDNA and ssDNA in their linkers. The linkers were constructed to span 86 bases of DNA, 
of which d = 62, 58, 50, 40, 30, or 20 bases were dsDNA. (B) Model predictions for the neutralization 
potency of these constructs. Data points show a representative in vitro neutralization assay of the 
3BNC60 Fab against HIV-1 strain 6535.3 (  13 replicates). 
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Fig. 4. Effects of extra long ssDNA in linkers on diFab potency. (A) Schematics of 3BNC60 diFabs. 
(B) Model predictions for the neutralization potency of these constructs. Data points show a 
representative in vitro neutralization assay of the 3BNC60 Fab against HIV-1 strain 6535.3 (  13 
replicates). 
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Fig. 5. Effects of gaps in dsDNA portions of diFab linkers on potency. (A) Schematics of 3BNC60 
diFabs with ssDNA gaps interspersed within the dsDNA portion of the linker. (B) Model predictions for the 
neutralization potency of these constructs. Data points show a representative in vitro neutralization assay 
of the 3BNC60 Fab against HIV-1 strain 6535.3 (  13 replicates). 
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